Hypertension and obesity

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S18-S22

  Diaz M E ^a  

^a Hospital Pasteur Montevideo   (Uruguay)

Author keywords

Hypertension; Obesity; Risk factors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; CENTRAL DEPRESSANT AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPID; SODIUM; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD VOLUME; BODY MASS; BODY WEIGHT; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONVALESCENCE; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG MECHANISM; FEMALE; GLUCOSE INTOLERANCE; HEALTH SURVEY; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PLASMA VOLUME; POPULATION RESEARCH; POPULATION RISK; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SLEEP APNEA SYNDROME; SODIUM LOAD; SODIUM RESTRICTION; TACHYCARDIA; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; URUGUAY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; URBAN POPULATION; URUGUAY;

EID: 0036228133     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001335     Document Type: Article

References (43)

1. Dustan HP. Hipertension y obesidad. Boone J Inter-Americana Clin Atenc Prim HipertensiOn Madrid 1991; 3: 525-540.
2. Bray GA. Complications of obesity. Ann Internal Med 1985; 103: 1052-1062.
3. Pi-Sunyer FX. Medical hazards of obesity. Ann Internal Med 1993; 119: 655-660.
4. Rosengren A, Wedel H, Wilhelmsen L. Weight and weight gain and coronary heart disease mortality. Eur Heart J 1999; 20: 246-248.
5. Rosengren A et al. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. Eur Heart J 1999; 20: 269-277.
6. Gunnell DJ, Smith GD. Weight, weight gain and coronary heart disease mortality. Eur Heart J 1999; 20: 246-248.
7. Peiris AN et al. Adiposity, fat distribution and cardiovascular risk. Ann Intern Med 1989; 110: 867-872.
8. Stallones RA. Epidemiologic studies of obesity. Ann Intern Med 1985; 103: 1003-1005.
9. Harrison GG. Height-weight tables. Ann Internal Med 1958; 103: 989-994.
10. Havlik RJ et al. Weight and hypertension. Ann Internal Med 1983; 98: 855-859.
11. Ali SS, Lester MA, Sowers JR. Metabolic abnormalities in hypertension. In: Oparil S, Weber MA (eds). Hypertension: A Companion to Brenner and Rector's The Kidney. W.B. Saunders: St Louis, 2000, pp 110-118.
12. Williams PT et al. Associations of dietary fat, regional adiposity and BP in men. JAMA 1987; 257: 3251-3256.
13. Bjorntorp P. Regional patterns of fat distribution. Ann Internal Med 1985; 103: 994-995.
14. Boyko EJ et al. Visceral adiposity, fasting plasma insulin, and BP in Japanese-americans. Diabetes Care 1995; 18: 174-181.
15. Kannel WB. Risk stratification in hypertension: new insight from the Framingham study. Am J Hypertens 2000; 13: 3S-10S.
16. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Dia-betologla 1994; 37: 948-952.
17. Manicardi V et al. Evidence for an association of high BP and hyperinsulinaemia in obese man. J Clin Endocrinol Metab 1986; 62: 1302-1304.
18. Hall JE. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994; 23: 38194.
19. Ashley Jr FW, Kannel WB. Relation of weight change to changes in atherogenic traits: Framinghan Study. J Chronica Dis 1974; 27: 103-104.
20. Stevens VJ et al. Weight loss Intervention in phase 1 of the trials of hypertension prevention. Arch Intern Med 1993; 153: 849.
21. Harlan WR et al. Blood pressure and nutrion in adults. The National Health and Nutrition Examination Survey. Am J Epidemiol 1984; 120: 17-28.
22. Jiang H et al. Dietary sodium intake and incidence of congestive heart failure in overweight u.s. men and women: Nhanes I. Epidemiologic follow-up study (NHEFS). Am J Hypertens 2000; 13: 6A.
23. Phillips BG et al. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J Hypertens 1999; 17: 297-300.
24. Millman RP et al. Body fat distribution and sleep apnea severity in women. Chest 1995; 107: 362-66.
25. Levinson PD et al. Adiposity and cardiovascular risk factors in men with obstructive sleep apnea. Chest 1993; 103: 1336-1342.
26. Diaz M, Dighiero M, Ghio R. Relationships between BP, the body mass index and the waist-hip ratio in Uruguay. Am J Hypertens 1996; 9: S75.
27. Wardle J. Obesity and behavior change: matching problems to practice. Intern J Obesity 1996; 20: S1-S8.
28. Moller DE, Bjorbaek C, Vidal-Puig A. Candidate genes for insuline resistance. Diabetes Care 1996; 19: 396-400.
29. Huey-Herng Sheu W, Lee WJ, Chen YT. High plasma leptin concentrations in hypertensive men but not in hypertensive women. J Hypertens 1999; 17: 1289-1295.
30. Sarzani R et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher BP in obese hypertensives. J Hypertens 1999; 17: 1301-1305.
31. Rumantir M et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 17: 1125-1133.
32. Grassi G. Obesity, sympathetic activity, sleep apnea. J Hypertens 1999; 17: 1059-1060.
33. Bao G, Metreveli N, Fletcher EC. Acute and chronic BP response to recurrent acoustic arousal in rats. AJH 1999; 12: 504-510.
34. Messerli FH et al. Obesity and essential hypertension. Arch Intern Med 1981; 141: 81-85.
35. Frohlich ED. Obesity hypertension. Converting enzyme inhibitors and calcium antagonists. Hypertension 1992; 19: 119-123.
36. Giles TD. Antihypertensive therapy and cardiovascular risk. Are all antihypertensives equal? Hypertension 1992; 19: 124-129.
37. Reisin E, Hutchinson HG. Obesity-hypertension: effects on the cardiovascular and renal system-the therapeutic approach. In: Oparil S, Weber MA (eds). A Companion to Brenner and Rector's The Kidney. W.B. Saunders: St Louis, 2000, pp 206-211.
38. Reyes AJ, Taylor SH. Diuretics in cardiovascular medicine: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther 1999; 13: 371-398.
39. Lithell H. Metabolic aspects of the treatment of hypertension. J Hypertens 1995; 13: S77-S80.
40. Lithell H. Hyperinsulinemia. Insulin resistance and the treatment of hypertension. Am J Hypertens 1996; 9: 150S-154S.
41. Langford HG et al. For the TAIM Research Group. Effect of drug and diet treatment of mild hypertension on diastolic BP. Hypertension 1991; 17: 211-217.
42. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 15: 1967-1975.
43. Diaz M, Dighiero M and Ghio R. Relationship between blood Pressure, the body mass index and the waist-hip ratio in Uruguay, LATIR study. Am J Hypertens 1996, 9:S75.